Emergent BioSolutions(EBS) - 2023 Q4 - Earnings Call Presentation

--- Total Segment Adjusted Gross Margin %2 1.All financial information incorporated within this presentation is unaudited. 2. See "End Notes: Non-GAAP Financial Measures" and "Appendix" for the definitions of non-GAAP terms and reconciliations to the most directly comparable GAAP financial measures. 15 FINANCIALS Key Financial Performance Metrics FY 2023 vs. FY 2022 (Continued)1 ($ in millions) FY 2022 FY 2023 SG&A $ --- $188.3 $96.8 $339.5 $368.4 30% 35% Cost of Commercial Product Sales Cost of MCM Product ...